While the first-generation TRIM24-specific drugs exerted poor antiproliferative effects [142], a selective TRIM24 degrader (dTRIM24), generated by the PROTAC strategy, inhibits cell proliferation and survival in acute leukemia [143]. The gene discussed is TRIM24; the disease is acute leukemia.